睿知中国医院研究地图
候选清单

正在招募B 细胞急性淋巴细胞白血病不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

ClinicalTrials.gov 上登记的一项B 细胞急性淋巴细胞白血病开放试验,由广东医科大学附属医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方广东医科大学附属医院Affiliated Hospital of Guangdong Medical University湛江医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06940960,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 12 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Refractory B-ALL: those who did not achieve complete remission after 2 courses of standard induction regimen chemotherapy, or those who did not achieve complete remission after first-line or multi-line salvage chemotherapy;

    入选标准第 5 条

    Relapsed B-ALL: relapse within 12 months after first remission, or relapse after first-line / multi-line salvage chemotherapy;

    入选标准第 6 条

    In addition, patients with Philadelphia chromosome positive (Ph +) should be relapsed after at least two tyrosine kinase inhibitors (TKI) treatment, or they could not tolerate TKI therapy, or have a t315i mutation, resistant to TKI drugs.

    入选标准第 8 条

    Subjects who have received other study drugs within 30 days before screening, or are still in the washout period;

    排除标准第 3 条

    Patients who have previously received any anti-CD19 / anti-Cluster of Differentiation 3(CD3) therapy or any other anti-CD19 therapy (except for those with normal T cell numbers and function and with CD19-positive tumors);

    排除标准第 4 条

    Patients who have been previously treated with any gene therapy product, including Chimeric Antigen Receptor T(CAR-T) therapy (except patients who do not have CAR-T cells in vivo and have normal T cell number and function and are with CD19 positive tumors);

    排除标准第 5 条

    Carcinoma in situ of cervical cancer or breast cancer, after curative treatment, showed no signs of recurrence for at least 3 years before the study;

    排除标准第 12 条

  3. Baseline Eastern Cooperative Oncology Group(ECOG) score was 0-1;

    入选标准第 13 条

  4. Glutamic aminotransferase (ALT) ≤3 times upper limit of normal (ULN);

    入选标准第 15 条

    Grass aminotransferase (AST) ≤3 times ULN;

    入选标准第 16 条

    Total bilirubin ≤1.5 times ULN;

    入选标准第 17 条

    Serum creatinine ≤ 1.5 times ULN, or creatinine clearance ≥ 60 mL/min;

    入选标准第 18 条

    Absolute neutrophil count (ANC)>1.000 / mm3;

    入选标准第 23 条

    Platelet≥50.000/mm3;

    入选标准第 25 条

    Hemoglobin>8.0 g/dl;

    入选标准第 26 条

  5. At least one measurable lesion was imaging for relapsed or refractory B cell lymphoma, long diameter of> 15mm, or extranodal lesion of> 10mm, along with a positive Positron Emission Tomography - Computed Tomography(PET-CT) examination.

    入选标准第 11 条

  6. Subjects with active hepatitis B (defined as Hepatitis B Virus(HBV) DNA test value> 500 IU / mL) or hepatitis C (HCV RNA positive); subjects with HIV positive or treponema pallidum positive;

    排除标准第 7 条

    The primary malignancy has been completely removed and is in complete remission for 5 years.

    排除标准第 13 条

  7. Female subjects in pregnant or lactating, or women with planned pregnancy within 2 years after JY231 infusion or male partner with planned pregnancy within 2 years after JY231 infusion;

    排除标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06940960,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Subject voluntarily sign informed consent and are willing and able to comply with all trial requirements;
  2. Age is 12-75 years old and gender is not limited;
  3. Malignancy cells in bone marrow or peripheral blood are Cluster of Differentiation 19 - positive(CD19+) detected by flow cytometric analysis;
  4. Meet the clinical criteria for relapsed or refractory B-cell lymphoma, including: indolent lymphoma (iNHL), such as follicular lymphoma (FL) and marginal zone lymphoma (MZL); aggressive B-cell lymphoma, like diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), and T-rich lymphocyte-bearing large B-cell lymphoma (TCRBCL), or have a diagnosis of acute B-lymphocytic leukemia (B-ALL) and meet one of the following conditions:
  5. Refractory B-ALL: those who did not achieve complete remission after 2 courses of standard induction regimen chemotherapy, or those who did not achieve complete remission after first-line or multi-line salvage chemotherapy;
  6. Relapsed B-ALL: relapse within 12 months after first remission, or relapse after first-line / multi-line salvage chemotherapy;
  7. Relapse after autologous or allogeneic hematopoietic stem cell transplantation;
  8. In addition, patients with Philadelphia chromosome positive (Ph +) should be relapsed after at least two tyrosine kinase inhibitors (TKI) treatment, or they could not tolerate TKI therapy, or have a t315i mutation, resistant to TKI drugs.
  9. Morphological examination of bone marrow cells showed the proportion of primitive and naive lymphocytes was> 5%;
  10. No Hematopoietic Stem Cell Transplantation(HSCT) within 6 months before enrollment;
  11. At least one measurable lesion was imaging for relapsed or refractory B cell lymphoma, long diameter of> 15mm, or extranodal lesion of> 10mm, along with a positive Positron Emission Tomography - Computed Tomography(PET-CT) examination.
  12. More than 12 weeks of expected survival period
  13. Baseline Eastern Cooperative Oncology Group(ECOG) score was 0-1;
  14. Adequate organ function (criteria regarding liver and kidney function can be moderately relaxed):
  15. Glutamic aminotransferase (ALT) ≤3 times upper limit of normal (ULN);
  16. Grass aminotransferase (AST) ≤3 times ULN;
  17. Total bilirubin ≤1.5 times ULN;
  18. Serum creatinine ≤ 1.5 times ULN, or creatinine clearance ≥ 60 mL/min;
  19. Indoor oxygen saturation ≥ 92%;
  20. Left ventricular ejection fraction (LVEF)≥55%, echocardiography confirmed no pericardial effusion and no clinically significant ECG findings;
  21. There is no clinically significant pleural effusion;
  22. Adequate bone marrow reserve without transfusion, defined as:
  23. Absolute neutrophil count (ANC)>1.000 / mm3;
  24. Absolute lymphocyte count (ALC)≥ 300 / mm3;
  25. Platelet≥50.000/mm3;
  26. Hemoglobin>8.0 g/dl;
  27. Subjects using the following drugs need to meet the following conditions:
  28. Steroids: The therapeutic dose of steroids must be stopped 72 hours before JY231 infusion. However, physiological alternative doses of steroids are allowed;
  29. Immunosuppression: Any immunosuppressive drug must be stopped at ≥4 weeks prior to enrollment;
  30. Antiproliferative therapy other than lymphodepletion chemotherapy within two weeks of infusion;
  31. Cluster of Differentiation 20(CD20) antibody-related therapy must be stopped within 4 weeks before infusion or 5 half-lives after the CD20 antibody;
  32. CNS disease prophylaxis must be stopped 1 week before JY231 infusion (e. g. intrathecal methotrexate).
  33. Reproductive men, sexual partners ensure effective contraception; fertile women, adopted effective contraception and agreed to use contraception throughout the study period.

排除标准:Exclusion Criteria:

  1. Subjects with active cerebrospinal fluid malignant cells or brain metastases, or subjects with active central nervous system (CNS) lymphoma, or CNS leukaemia;
  2. Subjects with a history of active CNS disease, such as seizures, cerebrovascular ischemia / hemorrhage, dementia, cerebellar disease, or any autoimmune disease associated with CNS involvement;
  3. Subjects who have received other study drugs within 30 days before screening, or are still in the washout period;
  4. Patients who have previously received any anti-CD19 / anti-Cluster of Differentiation 3(CD3) therapy or any other anti-CD19 therapy (except for those with normal T cell numbers and function and with CD19-positive tumors);
  5. Patients who have been previously treated with any gene therapy product, including Chimeric Antigen Receptor T(CAR-T) therapy (except patients who do not have CAR-T cells in vivo and have normal T cell number and function and are with CD19 positive tumors);
  6. Subjects with radiation therapy within 2 weeks prior to the infusion;
  7. Subjects with active hepatitis B (defined as Hepatitis B Virus(HBV) DNA test value> 500 IU / mL) or hepatitis C (HCV RNA positive); subjects with HIV positive or treponema pallidum positive;
  8. Subjects with uncontrolled acute life-threatening bacterial, viral, or fungal infection (e. g. positive blood culture 72 hours before infusion);
  9. Subjects with unstable angina pectoris and / or myocardial infarction within the 6 months prior to screening;
  10. Subjects with concurrent or previously diagnosed with other malignancies, except for the patients under following conditions:
  11. Well treated basal cells, papillary thyroid carcinoma, squamous cell carcinoma (adequate wound healing is required before enrollment into this study);
  12. Carcinoma in situ of cervical cancer or breast cancer, after curative treatment, showed no signs of recurrence for at least 3 years before the study;
  13. The primary malignancy has been completely removed and is in complete remission for 5 years.
  14. Arrhythmic subjects without medical management control;
  15. Subjects receiving oral anticoagulation within 1 week before JY231 injection infusion;
  16. Having active neurological autoimmune or inflammatory conditions (such as Guillain-Barre syndrome, amyotrophic lateral sclerosis);
  17. Female subjects in pregnant or lactating, or women with planned pregnancy within 2 years after JY231 infusion or male partner with planned pregnancy within 2 years after JY231 infusion;
  18. Subjects with taboo study procedures or other medical conditions that may put them at unacceptable risk according to the investigator's judgment and / or clinical criteria.
  19. Other conditions that the investigator believes that the subjects should not be enrolled in this clinical trial, such as poor compliance.

引自 ClinicalTrials.gov, NCT06940960, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06940960,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06940960